Microbot Historical Income Statement

MBOT Stock

USD 0.89 0.03 2.99%

Historical analysis of Microbot Medical income statement accounts such as Cost Of Revenue of 100.7 K can show how well Microbot Medical performed in making a profits. Evaluating Microbot Medical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Microbot Medical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Microbot Medical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Microbot Medical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Microbot Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Microbot Stock please use our How to Invest in Microbot Medical guide.

About Microbot Income Statement Analysis

Microbot Medical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Microbot Medical shareholders. The income statement also shows Microbot investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Microbot Medical Income Statement Chart

At this time, Microbot Medical's Interest Expense is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 14.3 M in 2024, despite the fact that Operating Income is likely to grow to (9.4 M).

Other Operating Expenses Total Operating Expenses Research Development Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Microbot Medical. It is also known as Microbot Medical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Microbot Medical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Microbot Medical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Microbot Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Microbot Stock please use our How to Invest in Microbot Medical guide.At this time, Microbot Medical's Interest Expense is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 14.3 M in 2024, despite the fact that Operating Income is likely to grow to (9.4 M).

Microbot Medical income statement Correlations

	Depreciation And Amortization	Interest Expense	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Discontinued Operations	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		-0.64	0.29	0.8	-0.7	-0.83	-0.81	0.05	0.72	-0.36	0.26	-0.34	0.6	0.79	0.33	0.32	-0.71	0.62	0.08	-0.64	-0.81	-0.83	-0.73
Interest Expense	-0.64		-0.02	-0.18	0.12	0.23	0.2	-0.13	-0.1	0.13	-0.11	0.49	-0.98	-0.17	-0.13	-0.18	0.1	-0.79	-0.09	0.79	0.82	0.77	0.71
Gross Profit	0.29	-0.02		0.5	-0.64	-0.49	-0.5	-0.9	0.58	-0.24	0.03	-0.17	0.01	0.19	0.03	-0.36	-0.12	0.02	-0.49	-0.02	-0.02	-0.03	-0.03
Other Operating Expenses	0.8	-0.18	0.5		-0.93	-0.99	-0.99	-0.22	0.99	-0.32	0.27	-0.37	0.18	0.93	0.53	0.39	-0.82	0.12	-0.03	-0.18	-0.38	-0.5	-0.48
Operating Income	-0.7	0.12	-0.64	-0.93		0.92	0.93	0.41	-0.94	0.29	-0.22	0.3	-0.13	-0.8	-0.49	-0.28	0.75	-0.13	0.15	0.12	0.27	0.43	0.35
Ebit	-0.83	0.23	-0.49	-0.99	0.92		1.0	0.2	-0.96	0.41	-0.39	0.36	-0.22	-0.92	-0.5	-0.37	0.79	-0.2	-0.08	0.21	0.43	0.53	0.49
Ebitda	-0.81	0.2	-0.5	-0.99	0.93	1.0		0.21	-0.97	0.41	-0.39	0.36	-0.19	-0.92	-0.5	-0.37	0.78	-0.17	-0.07	0.18	0.4	0.51	0.47
Cost Of Revenue	0.05	-0.13	-0.9	-0.22	0.41	0.2	0.21		-0.33	0.05	0.03	0.01	0.14	0.12	-0.09	0.34	-0.17	0.1	0.52	-0.1	-0.2	-0.26	-0.24
Total Operating Expenses	0.72	-0.1	0.58	0.99	-0.94	-0.96	-0.97	-0.33		-0.3	0.25	-0.37	0.11	0.89	0.51	0.33	-0.77	0.01	-0.09	-0.11	-0.27	-0.4	-0.41
Income Before Tax	-0.36	0.13	-0.24	-0.32	0.29	0.41	0.41	0.05	-0.3		-0.64	0.11	-0.1	-0.3	0.07	0.1	0.15	-0.1	-0.52	0.1	0.19	0.24	0.23
Total Other Income Expense Net	0.26	-0.11	0.03	0.27	-0.22	-0.39	-0.39	0.03	0.25	-0.64		0.0	0.07	0.27	0.05	0.05	-0.05	0.13	0.83	-0.13	-0.17	-0.15	-0.1
Net Income	-0.34	0.49	-0.17	-0.37	0.3	0.36	0.36	0.01	-0.37	0.11	0.0		-0.62	-0.36	-0.24	-0.22	0.28	0.03	0.03	-0.03	0.13	0.41	0.56
Income Tax Expense	0.6	-0.98	0.01	0.18	-0.13	-0.22	-0.19	0.14	0.11	-0.1	0.07	-0.62		0.18	0.14	0.19	-0.13	0.68	0.07	-0.71	-0.73	-0.76	-0.73
Research Development	0.79	-0.17	0.19	0.93	-0.8	-0.92	-0.92	0.12	0.89	-0.3	0.27	-0.36	0.18		0.53	0.54	-0.92	0.1	0.15	-0.16	-0.39	-0.52	-0.51
Selling General Administrative	0.33	-0.13	0.03	0.53	-0.49	-0.5	-0.5	-0.09	0.51	0.07	0.05	-0.24	0.14	0.53		0.91	-0.45	0.1	-0.04	-0.1	-0.19	-0.24	-0.23
Selling And Marketing Expenses	0.32	-0.18	-0.36	0.39	-0.28	-0.37	-0.37	0.34	0.33	0.1	0.05	-0.22	0.19	0.54	0.91		-0.49	0.13	0.18	-0.14	-0.26	-0.33	-0.32
Net Income From Continuing Ops	-0.71	0.1	-0.12	-0.82	0.75	0.79	0.78	-0.17	-0.77	0.15	-0.05	0.28	-0.13	-0.92	-0.45	-0.49		-0.1	-0.01	0.1	0.28	0.42	0.35
Non Recurring	0.62	-0.79	0.02	0.12	-0.13	-0.2	-0.17	0.1	0.01	-0.1	0.13	0.03	0.68	0.1	0.1	0.13	-0.1		0.06	-0.8	-0.87	-0.67	-0.45
Non Operating Income Net Other	0.08	-0.09	-0.49	-0.03	0.15	-0.08	-0.07	0.52	-0.09	-0.52	0.83	0.03	0.07	0.15	-0.04	0.18	-0.01	0.06		-0.07	-0.12	-0.15	-0.15
Discontinued Operations	-0.64	0.79	-0.02	-0.18	0.12	0.21	0.18	-0.1	-0.11	0.1	-0.13	-0.03	-0.71	-0.16	-0.1	-0.14	0.1	-0.8	-0.07		0.87	0.67	0.54
Interest Income	-0.81	0.82	-0.02	-0.38	0.27	0.43	0.4	-0.2	-0.27	0.19	-0.17	0.13	-0.73	-0.39	-0.19	-0.26	0.28	-0.87	-0.12	0.87		0.83	0.74
Net Interest Income	-0.83	0.77	-0.03	-0.5	0.43	0.53	0.51	-0.26	-0.4	0.24	-0.15	0.41	-0.76	-0.52	-0.24	-0.33	0.42	-0.67	-0.15	0.67	0.83		0.92
Reconciled Depreciation	-0.73	0.71	-0.03	-0.48	0.35	0.49	0.47	-0.24	-0.41	0.23	-0.1	0.56	-0.73	-0.51	-0.23	-0.32	0.35	-0.45	-0.15	0.54	0.74	0.92

Click cells to compare fundamentals

Microbot Medical Account Relationship Matchups

Microbot Medical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	84K	68K	76K	102K	(779K)	(740.1K)
Interest Expense	103K	80K	44K	131.3M	151.0M	158.5M
Gross Profit	(84K)	(68K)	(76K)	(102K)	(106K)	(100.7K)
Other Operating Expenses	7.2M	9.1M	11.4M	13.3M	9.9M	14.3M
Operating Income	(7.2M)	(9.1M)	(11.4M)	(13.3M)	(9.9M)	(9.4M)
Ebit	(7.2M)	(9.1M)	(11.4M)	(13.3M)	(9.9M)	(10.3M)
Ebitda	(7.2M)	(9.0M)	(11.3M)	(13.2M)	(10.6M)	(11.2M)
Cost Of Revenue	84K	68K	76K	102K	106K	100.7K
Total Operating Expenses	7.2M	9.1M	11.4M	13.3M	9.9M	18.8M
Income Before Tax	(7.2M)	(9.2M)	(11.3M)	(13.2M)	(10.7M)	(11.3M)
Total Other Income Expense Net	(7K)	(80K)	44K	113K	(885K)	(840.8K)
Net Income	(7.4M)	(9.2M)	(11.3M)	104.8M	(10.7M)	(11.3M)
Income Tax Expense	103K	80K	(44K)	(118M)	(106.2M)	(100.9M)
Research Development	3.0M	3.4M	6.2M	7.7M	5.7M	9.5M
Selling General Administrative	4.0M	5.6M	5.1M	5.4M	4.1M	3.9M
Net Income From Continuing Ops	(7.3M)	(9.2M)	(11.3M)	(13.2M)	(10.6M)	(11.1M)
Net Income Applicable To Common Shares	(7.2M)	(9.2M)	(11.3M)	(13.2M)	(15.1M)	(15.9M)
Interest Income	43K	16K	103K	54K	212K	222.6K
Net Interest Income	(103K)	(80K)	44K	54K	212K	222.6K
Reconciled Depreciation	84K	68K	76K	102K	104K	80.0K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Microbot Stock Analysis

When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Microbot Historical Income Statement

About Microbot Income Statement Analysis

Microbot Medical Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Microbot Medical income statement Correlations

Microbot Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Microbot Medical income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Microbot Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Total Revenue	Gross Profit
Other Operating Expenses	Operating Income
Ebit	Ebitda
Cost Of Revenue	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income	Income Tax Expense
Research Development	Selling General Administrative
Selling And Marketing Expenses	Net Income From Continuing Ops
Non Recurring	Non Operating Income Net Other
Net Income Applicable To Common Shares	Discontinued Operations
Interest Income	Net Interest Income
Reconciled Depreciation

Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 0.99	Other Operating Expenses
Research Development	+ 0.93	Other Operating Expenses
Ebitda	+ 0.93	Operating Income
Ebit	+ 0.92	Operating Income
Reconciled Depreciation	+ 0.92	Net Interest Income

Ebitda	- 0.99	Other Operating Expenses
Ebit	- 0.99	Other Operating Expenses
Income Tax Expense	- 0.98	Interest Expense
Total Operating Expenses	- 0.97	Ebitda
Total Operating Expenses	- 0.96	Ebit
Total Operating Expenses	- 0.94	Operating Income